Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare - Pharmaceutical Technology

InnoCare, which already has three approved therapies, describes itself as a biopharma focusing on cancer and autoimmune disease treatments. InnoCare, which already has three approved therapies, describes itself as a biopharma focusing on cancer and autoimmune disease treatments. Eli Lilly has conducted its fair share of deals in China already this year. Credit: PJ McDonnell/Shutterstock.com. Eli Lilly has partnered with China-based InnoCare Pharma in a five-drug strong research and license pact. As per the deal, Lilly will pay up to $100m upfront, with a further $3.25bn available in development and commercial milestone payments. InnoCare will also be in line for…

Source: Pharmaceutical Technology